Protalix Historical Cash Flow
| PLX Stock | USD 1.71 0.02 1.18% |
Analysis of Protalix Biotherapeutics cash flow over time is an excellent tool to project Protalix Biotherapeutics future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Net Income of 8.7 M or Total Cash From Financing Activities of 17.3 M as it is a great indicator of Protalix Biotherapeutics ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Protalix Biotherapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Protalix Biotherapeutics is a good buy for the upcoming year.
Protalix |
About Protalix Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Protalix balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Protalix's non-liquid assets can be easily converted into cash.
Protalix Biotherapeutics Cash Flow Chart
Add Fundamental
Begin Period Cash Flow
The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Protalix Biotherapeutics' cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Protalix Biotherapeutics current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Protalix Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. For more information on how to buy Protalix Stock please use our How to Invest in Protalix Biotherapeutics guide.At this time, Protalix Biotherapeutics' Issuance Of Capital Stock is fairly stable compared to the past year.
Protalix Biotherapeutics cash flow statement Correlations
Click cells to compare fundamentals
Protalix Biotherapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Protalix Biotherapeutics cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | (20.0M) | 473K | 20.7M | (21.9M) | 6.5M | 6.8M | |
| Free Cash Flow | (20.0M) | (26.8M) | (11.7M) | (25.6M) | (2.5M) | (2.6M) | |
| Change In Working Capital | (6.8M) | (27.1M) | 9.9M | (12.0M) | (10.5M) | (10.0M) | |
| Begin Period Cash Flow | 37.8M | 17.8M | 18.3M | 39.0M | 17.1M | 31.0M | |
| Other Cashflows From Financing Activities | (883K) | 472K | 46.2M | 2K | 712K | 676.4K | |
| Other Non Cash Items | 3.4M | 3.6M | 3.1M | (1.2M) | (638.0K) | (606.1K) | |
| Capital Expenditures | 627K | 655K | 1.5M | 628K | 1.1M | 1.5M | |
| Total Cash From Operating Activities | (19.4M) | (26.1M) | (10.3M) | (25M) | (1.3M) | (1.4M) | |
| Net Income | (18.3M) | (6.5M) | (27.6M) | (14.9M) | 8.3M | 8.7M | |
| End Period Cash Flow | 17.8M | 18.3M | 39.0M | 17.1M | 23.6M | 31.8M | |
| Depreciation | 1.6M | 1.3M | 1.1M | 1.1M | 1.2M | 2.0M | |
| Total Cashflows From Investing Activities | (883K) | (20.0M) | 18.9M | (5.0M) | (4.5M) | (4.3M) | |
| Other Cashflows From Investing Activities | (256K) | 703K | 327K | (4.4M) | (4.0M) | (3.8M) | |
| Change To Liabilities | (6.8M) | (23.9M) | 15.6M | (12.0M) | (10.8M) | (10.2M) | |
| Stock Based Compensation | 835K | 3.1M | 2.4M | 2.1M | 3.4M | 2.3M | |
| Change To Account Receivables | 188K | 2.1M | (1.0M) | (1.2M) | (428K) | (449.4K) | |
| Change To Inventory | 414K | (4.9M) | (4.9M) | 1.2M | (2.2M) | (2.4M) | |
| Change To Netincome | 835K | 2.8M | 3.6M | 556K | 639.4K | 607.4K | |
| Net Borrowings | (1.4M) | (4.8M) | (215K) | (34.1M) | (30.7M) | (29.2M) | |
| Change To Operating Activities | (592K) | (363K) | 190K | (5K) | (4.5K) | (4.3K) | |
| Investments | (883K) | (20M) | 18.9M | (5.0M) | (16.7M) | (15.9M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Protalix Stock Analysis
When running Protalix Biotherapeutics' price analysis, check to measure Protalix Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Protalix Biotherapeutics is operating at the current time. Most of Protalix Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Protalix Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Protalix Biotherapeutics' price. Additionally, you may evaluate how the addition of Protalix Biotherapeutics to your portfolios can decrease your overall portfolio volatility.